Product Reports Resources Pricing Login Book a demo

Sepax-tech

Biotech & Life Sciences · Newark, United States · Founded 2002

Better Surface Chemistry for Better Separation MoreLess

Sepax Technologies, Inc. is a specialized company that operates in the biotechnology market, providing high-tech solutions for the separation and analysis of biomolecules. Their products are primarily used in the pharmaceutical and biotech industries, serving clients who require precise and reliable methods for analyzing complex biological substances.

The company's main offerings include Proteomix® HIC Butyl columns and Monomix™ MC SEC resins. The Proteomix® HIC Butyl columns are used for high-resolution hydrophobic interaction separation of biomolecules, such as monoclonal antibodies (mAb), Antibody Drug Conjugates (ADCs), and their fragments. Simply put, these columns help to separate complex biological substances based on their hydrophobicity, or their tendency to repel water.

The Monomix™ MC SEC resins, on the other hand, are used for size exclusion chromatography (SEC), a method used to separate biomolecules based on their size. These resins are particularly stable and versatile, with a broad pH tolerance range and compatibility with many commonly used solvents and buffers.

Sepax Technologies also offers a full chromatographic separation solution for ADCs, which includes a range of products for the analysis of ADCs aggregate, monomer, fragment, and free drug. This comprehensive solution allows for detailed analysis of ADCs, which are complex molecules used in targeted cancer therapies.

The company's business model is based on selling these high-tech products and solutions to clients in the biotech and pharmaceutical industries. They also offer technical support to their clients, ensuring that their products are used effectively and efficiently.

Keywords: Biotechnology, Pharmaceutical Industry, Biomolecule Separation, Monoclonal Antibodies, Antibody Drug Conjugates, Hydrophobic Interaction Separation, Size Exclusion Chromatography, Technical Support, High-Tech Solutions, Chromatographic Separation.

Company overview

Sepax-tech company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2002
Headquarters
Newark, United States
Employees
87
Open positions
1
Dealroom signal
38.2
sub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorTech for Biotech and PharmasectorBiotech and PharmasectorHard TechsectorResinsectorDT and LSsectorscience-basedclient focusb2b

Valuation & funding

Sepax-tech funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Nov 2021 $69M $275M CITIC PE · Sinovac Biotech · Gan & Lee Pharmaceutical · Sherpa Venture Partners
SERIES COther financing Mar 2021 $28M $110M China Life Healthcare Fund · Fosun Capital
SERIES BOther financing Oct 2018 $7.3M $29M Huatai Zijin Investment · Suzhou Dunhang Investment Management
SERIES AOther financing Aug 2015 $0 Comway Capital
Showing 4 recorded eventsUnlock the complete deal history →

Growth signals

Sepax-tech website traffic

Latest recorded traffic for Sepax-tech is 5.3K monthly website visits, up 29.3% over the last three months. Sepax-tech's team grew 0% over the past year.

Latest monthly visits5.3K 3-month web change+29.3% 1-year team growth0%
Monthly website visits68 observations · Oct 2020–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Hiring

Open positions at Sepax-tech

Current openings linked to this company in Dealroom.

1 distinct opening shownExplore hiring signals →

Comparisons

Sepax-tech compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
PhaseVUses advanced algorithms to optimize clinical trials, improving success rates, efficiency, and uncovering hidden signals in the data Tel Aviv-Yafo, Israel Operational 71 $65M $200M
Comera Life SciencesEnhancing therapeutic protein formulations for better patient experience and extended product lifecycle Woburn, United States Operational
Wheeler BioBy bringing together biologics drug innovators, discovery CROs, and CDMOs accelerating the translation of therapeutic innovation to clinical impact Oklahoma City, United States Operational
Tesis LabsA unique integrated medical platform that is revolutionizing targeted genetic sequencing Phoenix, United States Operational
Celeris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases Graz, Austria Operational
Rubix strategiesA research and development company focusing on the gaps of product development toward effective patient outcomes through real-world evidence design and creating digital platforms for increasing patient diversity in Phase I/II clinical trials Lawrence, United States Operational
ExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening Oxford, United Kingdom Operational
EleusisLeusis is a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design London, United Kingdom Acquired
Showing 8 of the closest matchesCompare every metric →

Talent graph

Sepax-tech's talent

Book a demo to see the people
Employees 87 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

11 investors on Sepax-tech's cap table

Sourced from Dealroom's funding and investor records.

Series A 3 investors entered at this stage
Comway Capital
Huatai Zijin Investment
Suzhou Dunhang Investment Management
Series B+ 8 investors entered at this stage
China Life Healthcare Fund
Fosun Capital
CITIC PE
Sinovac Biotech
Gan & Lee Pharmaceutical
Sherpa Venture Partners
GL Ventures
Sinopharm Capital

Global footprint

Where Sepax-tech has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States80.8%
🇨🇳 China17.3%
🇬🇧 United Kingdom1.9%
3 countries shown

In the news

Latest news about Sepax-tech

Recent press, funding announcements, and product moves mentioning Sepax-tech — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Sepax-tech

An AI-synthesized read of the highest-engagement posts about Sepax-tech on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sepax-tech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.